Recent advances in the treatment of non-small cell lung cancer with MET inhibitors

Recent advances in the treatment of non-small cell lung cancer with MET inhibitors

Recently, research into the oncogenic driver genes associated with non-small cell lung cancer (NSCLC) has advanced significantly, leading to the development and clinical application of an increasing number of approved therapeutic agents. Among these, small molecule inhibitors that target mesenchymal...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dongna Zhang, Wenying Zhang, He Liu, Pan Liu, Chunxin Li, Yangyang Liu, Jicheng Han, Guangze Zhu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Chemistry
Subjects:	NSCLC MET inhibitors drug discovery structure-activity relationships targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fchem.2024.1501844/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer
by: Lijie Sima, et al.
Published: (2024-12-01)

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions
by: Kinsley Wang, et al.
Published: (2024-10-01)

Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context
by: Yang Xia, et al.
Published: (2025-03-01)

Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
by: Ratnakar Singh, et al.
Published: (2019-04-01)

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
by: R. Ben Dhiab, et al.
Published: (2025-06-01)

Review of real-world studies on capmatinib use in MET-mutated lung cancer
by: A. A. Kurylev, et al.
Published: (2025-04-01)

Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
by: Jian-Hui Wu, et al.
Published: (2025-06-01)

Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities  (2025 Version)
by: Jun CHEN, et al.
Published: (2025-02-01)

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration
by: Huijing Feng, et al.
Published: (2025-03-01)

Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies
by: Emeka Eze Joshua Iweala, et al.
Published: (2024-01-01)

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells
by: Dominic Leiser, et al.
Published: (2015-08-01)

The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma
by: Qilong Su, et al.
Published: (2025-06-01)

MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development
by: Dong Oh Moon
Published: (2024-12-01)

Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
by: David Spillane, et al.
Published: (2025-04-01)

c-MET Inhibition Reverses the Osimertinib Resistance in Lung Circulating Tumor Cell Clusters and Suppresses Metastasis
by: Zhipeng Zhang, et al.
Published: (2025-08-01)

In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors
by: Stuart Lutimba, et al.
Published: (2024-12-01)

Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer
by: Jiacheng Zhang, et al.
Published: (2025-05-01)

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
by: Yang Xia, et al.
Published: (2025-01-01)

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
by: Cristina Migliore, et al.
Published: (2018-07-01)

Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer
by: Kenneth K. W. To, et al.
Published: (2025-06-01)

Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report
by: Xinyi WANG, et al.
Published: (2024-12-01)

The MET Oncogene: An Update on Targeting Strategies
by: Simona Gallo, et al.
Published: (2024-11-01)

Berbamine as potential STING inhibitor For KRAS-mutant non-small cell lung cancer
by: Haoxin Yan, et al.
Published: (2025-06-01)

Changes in L‐phenylalanine concentration reflect and predict response to anti‐PD‐1 treatment combined with chemotherapy in patients with non‐small cell lung cancer
by: Yaqing Liu, et al.
Published: (2025-03-01)

Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET
by: Camilla Ruffilli, et al.
Published: (2025-01-01)

Methionine Aminopeptidase 2 (MetAP2) Inhibitor BL6 Attenuates Inflammation in Cultured Microglia and in a Mouse Model of Alzheimer’s Disease
by: Xiuli Zhang, et al.
Published: (2025-01-01)

Recent advances in therapeutic strategies for non-small cell lung cancer
by: Po-Lan Su, et al.
Published: (2025-03-01)

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
by: Esraa A. Abdelsalam, et al.
Published: (2022-12-01)

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data
by: Vera Damuzzo, et al.
Published: (2025-05-01)

Case Report: A rare case of MET-amplified gastric cancer with systemic metastasis: remarkable efficacy of crizotinib and the role of precision medicine
by: Yan Shen, et al.
Published: (2025-08-01)

Raddeanin A exerts potent efficacy against non-small cell lung cancer by inhibiting cyclin-dependent kinase 6
by: Xian Wang, et al.
Published: (2025-06-01)

NGS coverage accurately predicts MET and HER2 (ERBB2) gene amplifications in a real-world non-small cell lung cancer cohort
by: Adam Kowalewski, et al.
Published: (2025-07-01)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
by: Maicol Mancini, et al.
Published: (2017-12-01)

Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy
by: Ulas Kumbasar, et al.
Published: (2025-06-01)

Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors
by: Volkan Aslan, et al.
Published: (2025-05-01)

Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression
by: Kuan-Chang Lai, et al.
Published: (2025-07-01)

Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced Non‐Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives
by: Xingxiang Pu, et al.
Published: (2025-06-01)

Association between METS-VF and sarcopenia among middle-aged and older adults in China: The first longitudinal evidence from CHARLS
by: Tong Li, et al.
Published: (2025-07-01)

Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden
by: Hyungtai Sim, et al.
Published: (2024-12-01)